Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma
-
- Yoshida Misaki
- Department of Rheumatology, Kanazawa University Hospital, Japan
-
- Hara Satoshi
- Department of Rheumatology, Kanazawa University Hospital, Japan Medical Education Research Center, Graduate School of Medical Sciences, Kanazawa University, Japan
-
- Nishioka Ryo
- Department of Rheumatology, Kanazawa University Hospital, Japan
-
- Kobayashi Takafumi
- Department of Respiratory Medicine, Kanazawa University, Japan
-
- Murase Yuya
- Department of Respiratory Medicine, Kanazawa University, Japan
-
- Kimura Hideharu
- Department of Respiratory Medicine, Kanazawa University, Japan
-
- Mizushima Ichiro
- Department of Rheumatology, Kanazawa University Hospital, Japan
-
- Kawano Mitsuhiro
- Department of Rheumatology, Kanazawa University Hospital, Japan
説明
<p>Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs). There are a few case reports of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) as an irAE. We herein report a 49-year-old Japanese man who developed acute-onset polyarthralgia and edema of the back of both hands and bilateral lower legs after pembrolizumab administration for lung cancer. The patient's lung cancer was in complete remission, leading to the diagnosis of RS3PE induced by pembrolizumab rather than malignancy. When patients show RS3PE during ICI treatment, rheumatologists should consider the possibility of an irAE after excluding malignancy and systemic diseases. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 63 (14), 2089-2096, 2024-07-15
一般社団法人 日本内科学会